{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:21:27Z","timestamp":1783131687215,"version":"3.54.6"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>To study cerebrospinal fluid neurofilament light chain (CSF-NfL) levels as a prognostic biomarker in pediatric Guillain-Barr\u00e9 syndrome (GBS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Prospective study enrolling 26 pediatric GBS patients and 48 healthy controls (HCs) from neurology units between 2017 to 2021. The CSF-NfL levels were measured by enzyme-linked immunosorbent assay. The children's disability levels were evaluated using Hughes Functional Score (HFS) at nadir, 1 month, and 6 months after onset. The receiver operating characteristic (ROC) curve derived from logistic regression (with age as a covariate) was used to assess the prognostic value of CSF-NfL on the possibility of walking aided at 1 month after symptom onset.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The mean CSF-NfL levels were significantly increased in GBS patients (111.76 pg\/mL) as compared to that in HCs (76.82 pg\/mL) (<jats:italic>t<\/jats:italic> = 6.754, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). At follow- up, the mean CSF-NfL levels after treatment (65.69 pg\/mL) declined significantly (<jats:italic>t<\/jats:italic> = 6.693, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). CSF-NfL levels upon admission were significantly associated with the HFS at nadir (<jats:italic>r<\/jats:italic><jats:sub><jats:italic>s<\/jats:italic><\/jats:sub> = 0.461, <jats:italic>p<\/jats:italic> = 0.018). Moreover, the mean CSF-NfL levels in GBS patients with poor prognosis (130.47pg\/mL) were significantly higher than that in patients with good prognosis (104.87pg\/mL) (<jats:italic>t<\/jats:italic> = 2.399, <jats:italic>p<\/jats:italic> = 0.025). ROC curve analysis of the predictive value of CSF-NfL levels with respect to the inability to walk unaided within 1 month showed a significant difference (area under the curve: 0.857,95% confidence interval 0.702-1.000; <jats:italic>p<\/jats:italic> = 0.006).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CSF-NfL levels were increased in pediatric GBS patients. High CSF-NfL level predicted worse motor function, and was strongly associated with poor short-term prognosis of pediatric GBS. We propose a biomarker for early prediction of outcome in pediatric GBS, which would be applicable for clinical practice and efficacy of treatment in the future.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.972367","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T06:23:17Z","timestamp":1661149397000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Cerebrospinal fluid neurofilament light chain predicts short-term prognosis in pediatric Guillain-Barr\u00e9 syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Mei","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00415-020-10124-x","article-title":"Guillain\u2013Barr\u00e9 syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases","volume":"268","author":"Abu-Rumeileh","year":"2021","journal-title":"J Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"117267","DOI":"10.1016\/j.jns.2020.117267","article-title":"Nerve conduction studies in Guillain-Barr\u00e9 syndrome: influence of timing and value of repeated measurements","volume":"420","author":"Rath","year":"2021","journal-title":"J Neurol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/jnnp-2011-301882","article-title":"Outcome and its predictors in Guillain-Barre syndrome","volume":"83","author":"Rajabally","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(05)67665-9","article-title":"Guillain-Barr\u00e9 syndrome","volume":"366","author":"Hughes","year":"2005","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s00381-018-3856-0","article-title":"Guillain-Barr\u00e9 syndrome in children: subtypes and outcome","volume":"34","author":"Karalok","year":"2018","journal-title":"Child Nerv Syst."},{"key":"B7","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre' syndrome","volume":"76","author":"Walgaard","year":"2011","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"781787","DOI":"10.1002\/ana.21976","article-title":"Prediction of respiratory insufficiency in Guillain-Barr\u00e9 syndrome","volume":"67","author":"Walgaard","year":"2010","journal-title":"Ann Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1352458509359725","article-title":"Neurofilament light as a prognostic marker in multiple sclerosis","volume":"16","author":"Salzer","year":"2010","journal-title":"Mult Scler J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosur PS"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1212\/01.wnl.0000237334.69665.92","article-title":"CSF neurofilament levels: a potential prognostic marker in Guillain\u2013Barre' syndrome","volume":"67","author":"Petzold","year":"2006","journal-title":"Neurology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/2020.03.24.20042200","article-title":"Serum neurofilament light chain predicts long-term prognosis in Guillain-Barr\u00e9 syndrome patients","volume":"11","author":"Mart\u00edn-Aguilar","year":"2020","journal-title":"J Neurol Neurosur PS."},{"key":"B13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine."},{"key":"B14","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"Controlled trial prednisolone in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"Van den Berg","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1212\/WNL.0b013e3182904fcc","article-title":"Mortality in Guillain-Barre syndrome","volume":"80","author":"Van den Berg","year":"2013","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/jns5.12068","article-title":"Long-term outcome of Guillain-Barr\u00e9 syndrome in children","volume":"19","author":"Roodbol","year":"2014","journal-title":"J Peripher Nerv Syst."},{"key":"B18","doi-asserted-by":"publisher","first-page":"746389","DOI":"10.3389\/fneur.2021.746389","article-title":"Association between the rate of treatment response and short-term outcomes in childhood Guillain-Barr\u00e9 syndrome","volume":"12","author":"Jin","year":"2021","journal-title":"Front Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1023\/A:1010999509251","article-title":"Neurofilament protein synthesis and phosphorylation","volume":"29","author":"Grant","year":"","journal-title":"J Neurocytol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","article-title":"Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis","volume":"90","author":"Verde","year":"2019","journal-title":"J Neurol Neurosur PS."},{"key":"B21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/jns.12319","article-title":"Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy","volume":"24","author":"van Lieverloo","year":"2019","journal-title":"J Peripher Nerv Syst."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/acn3.790","article-title":"CSF Neurofilament light chain level predicts axonal damage in cerebral vasculitis","volume":"6","author":"Pawlitzki","year":"2019","journal-title":"Ann Clin Transl Neuro."},{"key":"B23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3233\/JND-200581","article-title":"Cerebrospinal fluid protein level and mechanical ventilation in Guillain-Barr\u00e9 syndrome patients","volume":"8","author":"Davalosa","year":"2021","journal-title":"J Neuromuscular Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12974-020-01737-0","article-title":"Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barr\u00e9 syndrome","volume":"17","author":"Altmann","year":"2020","journal-title":"J Neuroinflammation."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.972367\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T06:23:19Z","timestamp":1661149399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.972367\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":24,"alternative-id":["10.3389\/fneur.2022.972367"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.972367","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]},"article-number":"972367"}}